FutureGen

About FutureGen

FutureGen Biopharmaceutical (Beijing) Co., Ltd., also known as Mingji Biology (明济生物), operates as a biopharmaceutical company focused on developing innovative antibody-based therapeutics for oncology and autoimmune diseases. The company was initially founded in San Francisco in 2014 by a team of scientists with extensive experience in antibody drug development at multinational pharmaceutical firms. In 2018, the company established its presence in China, securing its A-round financing from Lilly Asia Ventures and officially registering its Beijing entity with Dr. Zhaoyu Jin as the legal representative and founder. The founder's team brings over two decades of experience in creating antibody drugs for cancer and immune disorders.

The company has built a comprehensive, end-to-end platform for large-molecule drug development. This internal capability spans the entire process from target discovery and validation to antibody screening, optimization, and CMC (Chemistry, Manufacturing, and Controls) production. A key asset is its proprietary Structure-based Targeted Evolution Platform (STEP) and Cell-based Antibody Panning (CAP) technologies. These platforms facilitate the rapid and efficient screening of antibody candidates with specific characteristics, aiming to develop best-in-class drugs. FutureGen's business model revolves around the in-house research and development of a pipeline of drug candidates and subsequent monetization through strategic partnerships and licensing agreements with larger pharmaceutical corporations. A significant milestone was the June 2024 licensing agreement with AbbVie for the global rights to FG-M701, a preclinical drug candidate for inflammatory bowel disease. This deal, valued at a potential $1.71 billion with an initial payment of $150 million, underscores the company's strategy of leveraging its R&D platform to generate non-dilutive funding to advance its broader pipeline.

FutureGen's drug pipeline includes multiple monoclonal and bispecific antibodies. Its most advanced asset, FG-M108 (also referred to as M108), is an ADCC-enhanced monoclonal antibody targeting CLDN18.2. This drug is in late-stage clinical trials for treating CLDN18.2-positive gastrointestinal cancers, such as pancreatic and stomach cancer, and has received Breakthrough Therapy Designation in China. The revenue from the FG-M701 deal is intended to fund the expensive Phase 3 trials for FG-M108. The company maintains R&D and production facilities in Beijing and a clinical team in Shanghai. Having secured approximately 400 million RMB through its Series A and B financing rounds, FutureGen is positioned to advance its pipeline, with a clear strategy of developing therapies primarily for high-prevalence cancers in China while also pursuing global partnership opportunities.